Flex Pharma Flex Pharma, Inc. (NASDAQ:FLKS) was founded in 2014 and is headquartered in Boston, Massachusetts, USA, with 20 full-time employees. It is a biotechnology company that develops and commercializes treatments related to neurological diseases and sports in the US The product of muscle cramps, twitches and cramps.
Flex Pharma, Flex Pharma, Inc. (FLKS):
Flex Pharmaceuticals is divided into two parts of operation : Consumer Operations and Drug Development.
Flex Pharma’s main drug candidate is FLX-787, a chemically synthesized single molecule and double transient receptor potential V1/A1 ion channel activator, which is undergoing exploratory phase II clinical trials in Australia for the treatment of multiple sclerosis Patients; and two phase II clinical trials in the United States for the treatment of motor neuron disease in amyotrophic lateral sclerosis.
Flex Pharma also offers HOTSHOT, a consumer beverage used to prevent and treat exercise-related muscle cramps. The company sells and sells its HOTSHOT products online through its e-commerce website and specialty retailers.